Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,277.51 +42.03 (+0.80%) Dow
38,686.32 +574.82 (+1.51%) Nasdaq
16,735.02 -2.08 (-0.01%) Bitcoin USD
68,905.09 +1,468.36 (+2.18%) CMC Crypto 200
1,490.04 +22.10 (+1.51%)
Nuvalent, Inc. (NUVL)
After hours:
| Previous close | 66.48 |
| Open | 66.35 |
| Bid | 65.47 x 300 |
| Ask | 65.81 x 400 |
| Day's range | 64.40 - 66.62 |
| 52-week range | 38.78 - 89.39 |
| Volume | |
| Avg. volume | 480,115 |
| Market cap | 4.236B |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:30 p.m. ET in NYC.
- PR Newswire
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more ALK tyrosine kinase inhibitors (TKIs).
- PR Newswire
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones, and reported first quarter 2024 financial results.
